Olaparib (new indication: metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and/or prednisone for patients in whom chemotherapy is not clinically indicated)



  • Active Substance: Olaparib
  • Name: Lynparza®
  • Therapeutic area: Prostate cancer
  • Pharmaceutical company: AstraZeneca GmbH


Time table:

  • Start: 15.01.2023
  • Final decision by G-BA: 06.07.2023


Final decision:

a1. Therapy-naïve patients with BRCA mutation: Hint for a considerable additional benefit
a2. Therapy-naïve patients without BRCA mutation (BRCA wild type): No additional benefit proved
b1. Pre-treated patients: No additional benefit proved